Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. The company develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.

Industry: Pharmaceutical Preparations Peers: Ayala Pharmaceuticals, Inc. Qrons Inc. International Stem Cell Corp Burzynski Research Institute Inc NovAccess Global Inc.